Status:
COMPLETED
Aberrant DNA Methylation to Predict Metachronous Gastric Neoplasms
Lead Sponsor:
Seoul National University Hospital
Conditions:
Metachronous Neoplasm
Gastric Cancer
Eligibility:
All Genders
Brief Summary
The study is a prospective cohort study to investigate whether aberrant DNA methylation can be useful for the prediction of metachronous recurrence after endoscopic resection of gastric neoplasms (dys...
Eligibility Criteria
Inclusion
- Patients who underwent endoscopic resection of gastric neoplasms (dysplasia or early gastric cancer)
- All gastric neoplasms at diagnosis should be curatively resected before enrollment.
Exclusion
- Previous history of all cancers.
- Previous history of gastrectomy
- Non-curative resection of gastric neoplasms
- Refusal to consent
Key Trial Info
Start Date :
September 11 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04830618
Start Date
September 11 2012
End Date
December 31 2020
Last Update
April 5 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.